Q-omics provides the consensus-scored BTF3P9 profile across patient tissues and cancer cell-line models. BTF3P9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BTF3P9 is differentially expressed in 6, with the highest sampling consensus in READ. Additionally, BTF3P9 RNA expression shows 5,979 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight KIRP, and READ as cancer lineages where BTF3P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3P9 survival associations across molecular data types. BTF3P9 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3P9 RNA expression–survival associations across cancer types. High BTF3P9 expression shows unfavorable associations in KIRP, STAD and ACC, but favorable associations in KIRC, CESC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for BTF3P9 RNA expression.
This table summarizes BTF3P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3P9 shows lower tumor expression in UCEC and LUAD and higher tumor expression in READ, LUSC, KIRP and LUAD. The READ box plot shows higher BTF3P9 RNA expression in tumor versus normal tissue (log2 FC = +0.730, t-test p = .036).
This table shows molecular features associated with BTF3P9 in patient tissues and cancer cell lines. In patient samples, BTF3P9 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
